116 related articles for article (PubMed ID: 8221692)
1. Increased expression of high mobility group protein I(Y) in high grade prostatic cancer determined by in situ hybridization.
Tamimi Y; van der Poel HG; Denyn MM; Umbas R; Karthaus HF; Debruyne FM; Schalken JA
Cancer Res; 1993 Nov; 53(22):5512-6. PubMed ID: 8221692
[TBL] [Abstract][Full Text] [Related]
2. Identification of high mobility group protein I(Y) as potential progression marker for prostate cancer by differential hybridization analysis.
Bussemakers MJ; van de Ven WJ; Debruyne FM; Schalken JA
Cancer Res; 1991 Jan; 51(2):606-11. PubMed ID: 1702360
[TBL] [Abstract][Full Text] [Related]
3. A retrospective study of high mobility group protein I(Y) as progression marker for prostate cancer determined by in situ hybridization.
Tamimi Y; van der Poel HG; Karthaus HF; Debruyne FM; Schalken JA
Br J Cancer; 1996 Aug; 74(4):573-8. PubMed ID: 8761372
[TBL] [Abstract][Full Text] [Related]
4. Expression profile of prostate-specific antigen messenger RNA assessed by in situ hybridization is a novel prognostic marker for patients with untreated prostate cancer.
Tsurusaki T; Koji T; Sakai H; Kanetake H; Saito Y
Clin Cancer Res; 1998 Sep; 4(9):2187-94. PubMed ID: 9748138
[TBL] [Abstract][Full Text] [Related]
5. The relationship of cathepsin B and stefin A mRNA localization identifies a potentially aggressive variant of human prostate cancer within a Gleason histologic score.
Sinha AA; Quast BJ; Korkowski JC; Wilson MJ; Reddy PK; Ewing SL; Sloane BF; Gleason DF
Anticancer Res; 1999; 19(4B):2821-9. PubMed ID: 10652560
[TBL] [Abstract][Full Text] [Related]
6. Prostate stem cell antigen (PSCA) expression in human prostate cancer tissues: implications for prostate carcinogenesis and progression of prostate cancer.
Zhigang Z; Wenlv S
Jpn J Clin Oncol; 2004 Jul; 34(7):414-9. PubMed ID: 15342669
[TBL] [Abstract][Full Text] [Related]
7. Tumor promoter induces high mobility group HMG-Y protein expression in transformation-sensitive but not -resistant cells.
Cmarik JL; Li Y; Ogram SA; Min H; Reeves R; Colburn NH
Oncogene; 1998 Jul; 16(26):3387-96. PubMed ID: 9692546
[TBL] [Abstract][Full Text] [Related]
8. Determination of high mobility group I(Y) expression level in colorectal neoplasias: a potential diagnostic marker.
Abe N; Watanabe T; Sugiyama M; Uchimura H; Chiappetta G; Fusco A; Atomi Y
Cancer Res; 1999 Mar; 59(6):1169-74. PubMed ID: 10096541
[TBL] [Abstract][Full Text] [Related]
9. Elevated high mobility group-I(Y) gene expression is associated with progressive transformation of mouse mammary epithelial cells.
Ram TG; Reeves R; Hosick HL
Cancer Res; 1993 Jun; 53(11):2655-60. PubMed ID: 8495429
[TBL] [Abstract][Full Text] [Related]
10. In situ hybridization studies of alpha 2-macroglobulin receptor and receptor-associated protein in human prostate carcinoma.
McGarvey T; Hussain MM; Stearns ME
Prostate; 1996 May; 28(5):311-7. PubMed ID: 8610058
[TBL] [Abstract][Full Text] [Related]
11. High mobility group protein HMGI(Y) enhances tumor cell growth, invasion, and matrix metalloproteinase-2 expression in prostate cancer cells.
Takaha N; Resar LM; Vindivich D; Coffey DS
Prostate; 2004 Jul; 60(2):160-7. PubMed ID: 15162382
[TBL] [Abstract][Full Text] [Related]
12. Insulin-like growth factor (IGF)-I, IGF-II and IGF type I receptor (IGFR-I) expression in prostatic cancer.
Cardillo MR; Monti S; Di Silverio F; Gentile V; Sciarra F; Toscano V
Anticancer Res; 2003; 23(5A):3825-35. PubMed ID: 14666684
[TBL] [Abstract][Full Text] [Related]
13. Quantitative immunohistochemical and in situ hybridization analysis of metalloproteinases in prostate cancer.
Cardillo MR; Di Silverio F; Gentile V
Anticancer Res; 2006; 26(2A):973-82. PubMed ID: 16619495
[TBL] [Abstract][Full Text] [Related]
14. Complete androgen ablation suppresses prostate stem cell antigen (PSCA) mRNA expression in human prostate carcinoma.
Zhigang Z; Wenlu S
Prostate; 2005 Dec; 65(4):299-305. PubMed ID: 16015594
[TBL] [Abstract][Full Text] [Related]
15. Group IIA phospholipase A as a prognostic marker in prostate cancer: relevance to clinicopathological variables and disease-specific mortality.
Mirtti T; Laine VJ; Hiekkanen H; Hurme S; Rowe O; Nevalainen TJ; Kallajoki M; Alanen K
APMIS; 2009 Mar; 117(3):151-61. PubMed ID: 19245588
[TBL] [Abstract][Full Text] [Related]
16. Increased expression of tumor-associated trypsin inhibitor, TATI, in prostate cancer and in androgen-independent 22Rv1 cells.
Paju A; Hotakainen K; Cao Y; Laurila T; Gadaleanu V; Hemminki A; Stenman UH; Bjartell A
Eur Urol; 2007 Dec; 52(6):1670-9. PubMed ID: 17306443
[TBL] [Abstract][Full Text] [Related]
17. Reduction of QM protein expression correlates with tumor grade in prostatic adenocarcinoma.
Altinok G; Powell IJ; Che M; Hormont K; Sarkar FH; Sakr WA; Grignon D; Liao DJ
Prostate Cancer Prostatic Dis; 2006; 9(1):77-82. PubMed ID: 16331298
[TBL] [Abstract][Full Text] [Related]
18. Aneusomies of chromosomes 8 and Y detected by fluorescence in situ hybridization are prognostic markers for pathological stage C (pt3N0M0) prostate carcinoma.
Takahashi S; Alcaraz A; Brown JA; Borell TJ; Herath JF; Bergstralh EJ; Lieber MM; Jenkins RB
Clin Cancer Res; 1996 Jan; 2(1):137-45. PubMed ID: 9816100
[TBL] [Abstract][Full Text] [Related]
19. Interphase cytogenetics of prostatic tumor progression: specific chromosomal abnormalities are involved in metastasis to the bone.
Alers JC; Krijtenburg PJ; Rosenberg C; Hop WC; Verkerk AM; Schröder FH; van der Kwast TH; Bosman FT; van Dekken H
Lab Invest; 1997 Nov; 77(5):437-48. PubMed ID: 9389787
[TBL] [Abstract][Full Text] [Related]
20. Detection of c-myc oncogene amplification and chromosomal anomalies in metastatic prostatic carcinoma by fluorescence in situ hybridization.
Jenkins RB; Qian J; Lieber MM; Bostwick DG
Cancer Res; 1997 Feb; 57(3):524-31. PubMed ID: 9012485
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
